CURE
Pharmaceutical Holdings (OTCQB:CURR) chairman William Yuan is transitioning to Chairman Emeritus and will remain in the company as a key advisor.
Rubén José King-Shaw Jr, who serves on the company’s board, opted to replace Yuan.
King-Shaw brings over thirty years of experience in healthcare technology and also private equity sectors.
Currently, he serves as CSO of Steward Health Care Systems, LLC.
In addition, the company appointed Dov Szapiro to its board. He serves as co-founder, managing partner and principal of Entourage Effect Capital.
“We thank Mr. Yuan for his dedicated leadership of CURE’s Board of Directors, and we are honored to have him stay with us as Chairman Emeritus and Key Advisor to the Board and executive team, as he leads the Company in its continued progress for dynamic international expansion and global revenue traction,” CURE chief executive Rob Davidson noted.
Press release content from Business Wire. The AP news staff was not involved in its creation.
CURE Pharmaceutical Announces Promotions and Additions to Board of Directors
February 11, 2021 GMT
OXNARD, Calif. (BUSINESS WIRE) Feb 11, 2021
CURE Pharmaceutical Holdings (“CURE” or the “Company”) (OTC: CURR), a holding company focused on the innovation of pharmaceutical technology, wellness products and drug delivery, announced today updates and additions to its Board of Directors.
ADVERTISEMENT
After a dedicated run as Chairman of the Board, William Yuan is stepping down and will continue to serve the Company as an advisor and Chairman Emeritus. Rubén José King-Shaw Jr, a highly qualified and respected member of the Board, has been selected to step into that role. Mr. King-Shaw brings with him three decades of executive leadership experience in the healthcare technology and private equity sectors. He recently served on the board of Atlanta-based Cotiviti Holdings, Inc. an